BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Company Developments Business Wire NEW YORK & PETACH TIKVAH, Israel -- August 14, 2013 BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, August 20, 2013 at 8:45 a.m. Eastern Daylight Time, 15:45 Israel Daylight Time. Mr. Chaim Lebovits, President and Principal Executive Officer, will update shareholders on the recent public offering and other company developments. The call will be conducted in English, with Q&A in both English and Hebrew. Callers may participate in the conference call by dialing: USA:1-888-407-2553 Israel: 03-918-0644 International:+972-3-918-0644 Callers are invited to ask relevant questions in English or Hebrew during the conference call. Questions may also be pre-submitted firstname.lastname@example.org prior to 7:00 a.m. EDT on Monday, August 19, 2013. A recording of the conference will be available for download Wednesday, August 21, 2013 from the company’s website. About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com. Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may,” “should,” “would,” “could,” “will,” “expect,” “likely,” “believe,” “plan,” “estimate,” “predict,” “potential,” and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Contact: BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI) Mr. Chaim Lebovits, President +972-3-9236384 email@example.com www.brainstorm-cell.com
BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Company Developments
Press spacebar to pause and continue. Press esc to stop.